Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Sales Slowdown Reflects Overall Rx Market Trend, Pfizer Says

Executive Summary

A slowdown in the growth rate for Lipitor reflects the softness in overall prescription demand during the first quarter, Pfizer suggested during an April 22 earnings conference call

You may also be interested in...



Schering/Merck Ready For Vytorin; Lipid Market Growth Returns

Schering-Plough and Merck are likely to price the Zocor/Zetia combination Vytorin on par with Pfizer's Lipitor, Merck indicated during an April 22 conference call

Schering/Merck Ready For Vytorin; Lipid Market Growth Returns

Schering-Plough and Merck are likely to price the Zocor/Zetia combination Vytorin on par with Pfizer's Lipitor, Merck indicated during an April 22 conference call

Lipitor Scripts Rebounding, Pfizer Says; Cholesterol Category Still Has Life

Pfizer sees signs of a rebound in Lipitor (atorvastatin) prescriptions over the past six weeks, U.S. Pharmaceuticals President Pat Kelly said during Pfizer's June 17 analysts meeting in New York

Related Content

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel